Albumin nanospheres as carriers for passive drug targeting: An optimized manufacturing technique

被引:116
作者
Muller, BG
Leuenberger, H
Kissel, T
机构
[1] UNIV MARBURG,DEPT PHARMACEUT & BIOPHARM,D-35032 MARBURG,GERMANY
[2] SANDOZ PHARMA LTD,PHARMA DEV,DRUG DELIVERY SYST DEPT,BASEL,SWITZERLAND
[3] UNIV BASEL,SCH PHARM,BASEL,SWITZERLAND
关键词
albumin; nanospheres; manufacturing; glutaraldehyde; cross-linking; central composite design;
D O I
10.1023/A:1016064930502
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to develop a new method to produce albumin particles in the sub-200-nanometer range with a narrow size distribution and in a controlled and reproducible manner. Methods. A new emulsion crosslinking method was developed using ultrasound and static mixing as homogenization steps and a central composite design was used to evaluate the influence of different process parameters on particle size, polydispersity and yield. Results. Response surface analysis allowed the location of the most important factors. Of all the factors investigated, only the albumin concentration and the aqueous phase volume showed a significant influence on response parameters. Albumin nanospheres with sizes below 200 nm in diameter and very narrow size distributions were obtained in high yields (>80%). Conclusions. This study describes a new preparation method for albumin nanoparticles which are suitable for future drug targeting studies.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 13 条
  • [1] ALBUMIN MICROSPHERES AND MICROCAPSULES - METHODOLOGY OF MANUFACTURING TECHNIQUES
    ARSHADY, R
    [J]. JOURNAL OF CONTROLLED RELEASE, 1990, 14 (02) : 111 - 131
  • [2] Box G. E. P., 1987, Empirical model-building and response surfaces
  • [3] DERRINGER G, 1980, J QUAL TECHNOL, V12, P214, DOI 10.1080/00224065.1980.11980968
  • [4] ALBUMIN MICROSPHERES .2. APPLICATIONS IN DRUG DELIVERY
    GUPTA, PK
    HUNG, CT
    [J]. JOURNAL OF MICROENCAPSULATION, 1989, 6 (04) : 463 - 472
  • [5] ILLUM L, 1982, INT J PHARM, V12, P135
  • [6] LEUENBERGER H, 1991, PHARM TECHNOLOGIE
  • [7] Muller B. G., 1993, PHARM PHARM LETT, V3, P67
  • [8] OSTROWSKI N, 1988, PARTICLE SIZE ANAL 1
  • [9] ROSER M, 1993, EUR J PHARM BIOPHARM, V39, P8
  • [10] TOMLINSON E, 1985, METHOD ENZYMOL, P27